Ground News

Don't Just Read the News, Understand It.

breakthrought1d.ca image

News from breakthrought1d.ca

See all of breakthrought1d.ca news coverage in one place. Discover how breakthrought1d.ca’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 9 headlines written by breakthrought1d.ca during the past 3 months.

Ground News rates breakthrought1d.ca’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

breakthrought1d.ca’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about breakthrought1d.ca

Where is breakthrought1d.ca located?breakthrought1d.ca's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top breakthrought1d.ca News

Jim Beatty – navigating an adult diagnosis in the spotlight

Victoria, British Columbia · Victoria

Jim Beatty – navigating an adult diagnosis in the spotlight

Jim Beatty is a passionate volunteer in the fight against type 1 diabetes. For many years, Jim has volunteered with the JDRF, and now Breakthrough T1D, emceeing events and participating on various committees. Jim has been living with type 1 diabetes for more than 20 years, following his adult diagnosis. Jim is a former journalist who now operates his own communications company in Victoria, B.C., where he likes to hike, fish and enjoy the West C…Read Article

Health Canada approves Tzield – the first ever disease modifying therapy for type 1 diabetes

On May 5, 2025, Sanofi announced Health Canada approval of Tzield, the first disease-modifying therapy for type 1 diabetes (T1D). This is a huge win for the T1D community in that it is the first medicine to be approved in Canada that addresses the autoimmunity behind T1D – not just the symptoms that is causes. […]Health Canada · Canada See the Story

Breakthrough T1D Canada’s Mental Health Strategy: where we are today

May is Mental Health Awareness month, a national movement to raise awareness of the importance of mental health and the structural gaps that exist in accessing treatment and support. Mental health is central to living well with type 1 diabetes (T1D). This is why, in 2021, Breakthrough T1D Canada launched its Mental Health Strategy, with the goal of better supporting mental health in people with T1D, while we continue to support research towards…Mental Health · British Columbia Read Article

Faces of the $100M Campaign to Accelerate: Lynn’s story

From years of burdensome insulin injections to the insulin pump that saved her life. Lynn Cameron is a passionate advocate at Breakthrough T1D, fiercely pursuing positive change for Quebec’s type 1 diabetes (T1D) community, which desperately requires public coverage of T1D devices. Lynn has lived with this autoimmune disease for nearly 60 years, many of which she endured without access to the advanced technology she needed to thrive. Over the pa…Montreal · Montreal Read Article

Exciting update on Canadian-made device research

Dr. Mahla Poudineh (University of Waterloo), in collaboration with Dr. Leyla Soleymani (McMaster University), is developing a wearable continuous ketone monitor, which can indicate a life-threatening condition called diabetic ketoacidosis (DKA). This device combines novel biology (ketone measurement) with novel engineering (hydrogel microneedles) to produce a groundbreaking new device – the Wearable Aptalyzer. Biology: Similar to a continuous gl…Waterloo, Ontario · Waterloo Read Article

Important update on Vertex trials

100% Center coverage: 1 sources

A large area of cure-based T1D research is investigating stem cell-based therapy. The goal of this approach is to use stem cells as a renewable source of insulin-producing cells which, when transplanted, would replace beta cells that are destroyed in a person with T1D, thereby allowing them to produce insulin again. This would lessen or eliminate the amount of external insulin required by someone living with T1D (either by injection, pen, or pum…Business · Boston See the Story

Newly public Beta Bionics reports sales surge; Dexcom hires CCO

100% Center coverage: 1 sources

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.See the Story

You've scrolled to the bottom of the feed, there are no more stories.